Panel Discussion - Nuke 'em From Orbit: Radiotherapy Time: 9:30am ET SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will be available for one-on-one meetings with investors in the following upcoming investor conferences as well as a panel discussion as not ...

Panel Discussion - Nuke 'em From Orbit: Radiotherapy Time: 9:30am ET About Perspective Therapeutics, Inc. Perspective Therapeutics, Inc., is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics ...

Nvidia (NASDAQ:NVDA) is having a fantastic year in the markets, up 156% in 2024. That follows a 2023 return of 239%. Surprisingly, there are a few U.S.-listed stocks outperforming Nvidia this year. Root (ROOT) Root (NASDAQ:ROOT) is up 644% year-to-date, more than 4x Nvidia's return. It's certainly been a breakout year for the Insurtech stock. In February, it reported its best Q4 results in its history and the shares gained 87% in a single week. "By investing in our differentiated technology across our three ...

SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its second quarter 2024 financial results and provide a business update on Monday, August 12, 2024 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-re ...

The mean estimate comprises four short-term price targets with a standard deviation of $5.38. While the lowest estimate of $17 indicates a 37.8% increase from the current price level, the most optimistic analyst expects the stock to surge 135% to reach $29. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. But, for CATX, an impressive average price target is not the o ...

SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to an updated list of additions to the membersh ...

The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and ...

At Perspective's annual meeting of stockholders on May 31, 2024, Perspective's stockholders approved a proposal to authorize Perspective's Board of Directors to file an amendment to the Company's certificate of incorporation to effect the reverse stock split at a ratio of 1-for-10. The reverse stock split will be effected by filing a Certificate of Amendment to Perspective's certificate of incorporation with the Secretary of State of the State of Delaware. The reverse split will affect all issued and outsta ...

SEATTLE, June 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will effect a 1-for-10 reverse stock split, effective at 4:01 p.m. Eastern time on June 14, 2024. Beginning with the opening of trading on June 17, 2024, Perspective's common stock is expected to begin trading on the NYSE American on a split-ad ...

SEATTLE, June 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc.("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced six updates featuring the Company's alpha-particle radiopharmaceuticals at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting, that was held on June 8-11, 2024, in Toronto Canada. Summary: This presentation outlines the de ...